Dmitry Familtsev
Interventional Cardiology · Rolla, MONPI 1194161174
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $614 and has fallen 58.8% since, to $253 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MO, where the typical reported total is $10,448.
Across 126 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$313
- E.r. Squibb & Sons, L.L.C.$302
- Johnson & Johnson$234
- Novo Nordisk$232
- Amgen$223
- Novartis$216
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,46291%
- Education$2329%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 17 | $313 |
| E.r. Squibb & Sons, L.L.C. | 14 | $302 |
| Johnson & Johnson | 13 | $234 |
| Novo Nordisk | 2 | $232 |
| Amgen | 15 | $223 |
| Novartis | 12 | $216 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $167 |
| Boston Scientific | 2 | $165 |
| Amarin Pharma, Inc. | 9 | $140 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| Lundbeck LLC | 4 | $79 |
| Bayer | 4 | $78 |
| Pfizer | 5 | $74 |
| Merck | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Akcea Therapeutics, Inc. | 1 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| AstraZeneca | 2 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Philips North America LLC | 1 | $25 |
| Apria Healthcare LLC | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,694 in reported general payments places this provider in the 20th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 216 | $180,392 |
| EntrestoSacubitril/Valsartan | 50 | $70,869 |
| JardianceEmpagliflozin | 30 | $28,655 |
| XareltoRivaroxaban | 26 | $25,437 |
| BrilintaTicagrelor | 17 | $11,743 |
| Repatha SureclickEvolocumab | 16 | $9,725 |
| Praluent PenAlirocumab | 15 | $7,487 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $6,746 |
| Metoprolol Succinate | 267 | $4,228 |
| Ranolazine ErRanolazine | 28 | $2,412 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 73 | $2,279 |
| Rosuvastatin Calcium | 200 | $2,164 |
| Potassium Chloride | 79 | $1,438 |
| Atorvastatin Calcium | 173 | $1,274 |
| Lisinopril | 207 | $1,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $74 | $180,392216 claims |
| NovartisEntresto | $216 | $70,86950 claims |
| Boehringer IngelheimJardiance | $313 | $28,65530 claims |
| Johnson & JohnsonXarelto | $234 | $25,43726 claims |
| AstraZenecaBrilinta | $29 | $11,74317 claims |
| Esperion Therapeutics, Inc.Nexlizet | $32 | $6,74613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Rolla
- Stilianos EfstratiadisRolla$34K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.